Senescent Cancer Cells Are Vulnerable to Extrinsic Apoptosis Pathway Activation

Area of Science:

• Cellular senescence
• Apoptosis induction
• Targeted cancer therapy

Background:

• Cellular senescence is a state of irreversible cell cycle arrest.
• Senescent cells accumulate with age and contribute to age-related diseases.
• Targeting senescent cells (senolysis) is a promising therapeutic strategy.

Purpose of the Study:

• To investigate the efficacy of Death Receptor 5 (DR5) activation in eliminating senescent cells.
• To determine if Bromodomain-containing protein 2 (BRD2) inhibition can enhance DR5-mediated senolysis.

Main Methods:

• Utilized senolytic agents targeting DR5.
• Employed BRD2 inhibitors in combination with DR5 activators.
• Assessed cell viability and apoptosis markers in senescent cell models.

Main Results:

• DR5 activation demonstrated potent senolytic activity, efficiently killing senescent cells.
• Co-administration of BRD2 inhibitors significantly potentiated the senolytic effect of DR5 activation.
• Inhibition of BRD2 enhanced the apoptotic signaling downstream of DR5.

Conclusions:

• DR5 activation is a viable strategy for senolysis.
• Combining DR5 activation with BRD2 inhibition offers a synergistic approach to enhance senolytic therapy.
• This combination strategy holds potential for treating diseases associated with senescent cell accumulation.